Form 4: VolitionRx Secretary Awarded 15,223 RSUs

VolitionRx Ltd. Secretary Rodney Gerard Rootsaert received an award of 15,223 restricted stock units in lieu of cash compensation, vesting through early 2026.

Summary

• Rodney Gerard Rootsaert, Secretary of VolitionRx Ltd. (VNRX), was awarded 15,223 restricted stock units (RSUs) on August 15, 2025.
• The RSUs were granted under the company's 2015 Stock Incentive Plan as compensation in lieu of cash.
• The RSUs will be earned in six approximately equal monthly installments, commencing on September 1, 2025.
• Additional time-based vesting will occur in two installments: 7,612 units on November 1, 2025, and 7,611 units on February 1, 2026.
• Vesting is generally contingent upon Mr. Rootsaert's continued service to the company.
• Upon vesting and settlement, Mr. Rootsaert will receive common stock shares equivalent to the number of vested RSUs.
• Following this transaction, Mr. Rootsaert directly beneficially owns 149,233 shares of common stock and 15,223 RSUs.
• He also indirectly beneficially owns 1,007,718 shares of common stock through Concord International, Inc., where he is a controlling director.

Sentiment

Score: 7

Explanation: The award of restricted stock units to a key executive is a positive for aligning management incentives with shareholder interests and conserving cash. However, it is a routine compensation event and does not indicate extraordinary operational performance or strategic shifts.

Positives

• The award of restricted stock units aligns management's interests with shareholders by providing equity-based compensation.
• Utilizing RSUs in lieu of cash compensation can help conserve the company's cash reserves.

Negatives

• The issuance of RSUs, upon vesting and settlement, will result in a slight dilution of existing shareholder equity.

Risks

• The vesting of RSUs is contingent on continued service, meaning the full benefit is not guaranteed if the reporting person's employment ceases.
• The value of the RSUs upon vesting is subject to the future market price of VolitionRx common stock.

Future Outlook

The future value of the awarded restricted stock units is directly tied to the company's stock performance through the vesting periods ending in February 2026, contingent on the reporting person's continued service.

Industry Context

Equity-based compensation, such as restricted stock units, is a standard practice across various industries, particularly in biotechnology and life sciences, to attract, retain, and incentivize key executives and align their long-term interests with shareholder value creation. This practice is common for companies like VolitionRx, which often rely on long-term strategic development and innovation.

Comparison to Industry Standards

• The use of restricted stock units as a form of executive compensation is a widely accepted practice, comparable to compensation structures seen in similar-sized biotechnology and diagnostic companies.
• While specific RSU grants vary by company and executive role, the principle of linking executive incentives to future company performance through equity is a global benchmark.
• For instance, companies like Exact Sciences (EXAS) or Guardant Health (GH) also utilize significant equity components in their executive compensation packages to foster long-term commitment and performance.

Related Party Transactions

• Rodney Gerard Rootsaert indirectly beneficially owns 1,007,718 shares of common stock through Concord International, Inc., where he is a controlling director and shares voting and dispositive control.

Stakeholder Impact

• Shareholders: Potential minor dilution upon RSU vesting; improved alignment of executive incentives with long-term company performance.
• Management: Rodney Gerard Rootsaert receives equity compensation, incentivizing continued service and performance.

Next Steps

• Continued service by Rodney Gerard Rootsaert to ensure earning and vesting of RSUs.
• Monthly earning of RSUs commencing September 1, 2025.
• Vesting of 7,612 RSUs on November 1, 2025.
• Vesting of 7,611 RSUs on February 1, 2026.

Key Dates

Recommendation

This Form 4 filing reports a routine equity compensation award to a company executive. While it aligns management incentives with shareholder interests and conserves cash, it does not present new information that would fundamentally alter the investment thesis for VolitionRx. The transaction is an expected part of executive compensation and does not warrant a change in investment recommendation based solely on this filing.

Keywords

VolitionRx, VNRX, SEC Form 4, Restricted Stock Units, RSU, Equity Compensation, Insider Trading, Executive Compensation, Stock Incentive Plan, Beneficial Ownership